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Impact of oral meloxicam on circulating physiological biomarkers of stress
and inflammation in beef steers after long-distance transportation
Abstract
Transportation stress can result in significant economic losses to producers due to decreased animal
productivity and increased medication costs associated with sickness such as bovine respiratory disease
(BRD). Meloxicam (MEL) provides pain relief and anti-inflammatory effects in cattle for several days after a
single oral treatment. Our hypothesis was that MEL administration before shipping would reduce the impact
of long-distance transportation on circulating physiological biomarkers of stress and inflammation in beef
steers. Ninety-seven beef steers were blood sampled for baseline biomarker determination and then randomly
assigned to receive either 1 mg/kg MEL (n = 49) or a placebo (CONT; n = 48) per os before a 1,316-km
transportation event lasting approximately 16 h. Calves were then blood sampled on arrival and 5 d later.
Changes in the hemogram, circulating plasma proteins, total carbon dioxide (TCO2), fibrinogen, substance P
(SP), cortisol, haptoglobin (Hp)-matrix metalloproteinase-9 (MMP-9) complexes, and tumor necrosis factor
α (TNFα) between treatments over time were compared using a mixed effects model with statistical
significance designated as P < 0.05. Analysis of covariance was conducted to assess the relationship between
circulating MEL concentrations and biomarker changes over time. An increase in neutrophil, platelet,
monocyte, white blood cell, and red blood cell counts occurred after transportation (P < 0.0001) and a
decrease in lymphocyte count were observed (P < 0.0001). Meloxicam treatment reduced the stress-induced
neutrophilia (P = 0.0072) and circulating monocyte count (P = 0.013) on arrival. Mean corpuscle
hemoglobin (P = 0.05), mean corpuscle volume (P = 0.05), and lymphocyte count (P = 0.05) were also
greater in the CONT calves compared with MEL calves after transportation. Furthermore, Hp-MMP-9
complexes, TCO2, TNFα, plasma proteins, and SP increased and cortisol decreased after shipping (P < 0.01).
Meloxicam treatment tended to reduce serum cortisol concentrations (P = 0.08) and there was evidence of a
time × treatment interaction (P = 0.04). An inverse relationship between plasma MEL concentrations and
circulation cortisol concentrations (P = 0.002) and neutrophil (P = 0.04) and basophil counts (P = 0.03) was
also observed. The results suggest that MEL administration may reduce the impact of long-distance
transportation on circulating physiological biomarkers of stress and inflammation in beef calves.
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ABSTRACT: Transportation stress can result in sig-
nificant economic losses to producers due to decreased 
animal productivity and increased medication costs 
associated with sickness such as bovine respiratory dis-
ease (BRD). Meloxicam (MEL) provides pain relief and 
anti-inflammatory effects in cattle for several days after 
a single oral treatment. Our hypothesis was that MEL 
administration before shipping would reduce the impact 
of long-distance transportation on circulating physi-
ological biomarkers of stress and inflammation in beef 
steers. Ninety-seven beef steers were blood sampled for 
baseline biomarker determination and then randomly 
assigned to receive either 1 mg/kg MEL (n = 49) or a 
placebo (CONT; n = 48) per os before a 1,316-km trans-
portation event lasting approximately 16 h. Calves were 
then blood sampled on arrival and 5 d later. Changes in 
the hemogram, circulating plasma proteins, total carbon 
dioxide (TCO2), fibrinogen, substance P (SP), cortisol, 
haptoglobin (Hp)-matrix metalloproteinase-9 (MMP-9) 
complexes, and tumor necrosis factor α (TNFα) between 
treatments over time were compared using a mixed 
effects model with statistical significance designated 
as P < 0.05. Analysis of covariance was conducted to 
assess the relationship between circulating MEL concen-
trations and biomarker changes over time. An increase 
in neutrophil, platelet, monocyte, white blood cell, 
and red blood cell counts occurred after transportation 
(P < 0.0001) and a decrease in lymphocyte count were 
observed (P < 0.0001). Meloxicam treatment reduced 
the stress-induced neutrophilia (P = 0.0072) and circulat-
ing monocyte count (P = 0.013) on arrival. Mean cor-
puscle hemoglobin (P = 0.05), mean corpuscle volume 
(P = 0.05), and lymphocyte count (P = 0.05) were also 
greater in the CONT calves compared with MEL calves 
after transportation. Furthermore, Hp-MMP-9 complex-
es, TCO2, TNFα, plasma proteins, and SP increased and 
cortisol decreased after shipping (P < 0.01). Meloxicam 
treatment tended to reduce serum cortisol concentrations 
(P = 0.08) and there was evidence of a time × treatment 
interaction (P = 0.04). An inverse relationship between 
plasma MEL concentrations and circulation cortisol con-
centrations (P = 0.002) and neutrophil (P = 0.04) and 
basophil counts (P = 0.03) was also observed. The results 
suggest that MEL administration may reduce the impact 
of long-distance transportation on circulating physiologi-
cal biomarkers of stress and inflammation in beef calves.
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INTRODUCTION
Transportation of calves intended for beef produc-
tion is a common practice. In the United States, at least 
65% of calves are shipped to feedlots in Texas, Kan-
sas, Nebraska, and Colorado, usually by truck, due to 
a geographical separation between calf rearing and 
finishing facilities (Swanson and Morrow-Tesch, 2001; 
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U.S Food and Drug Administration, 1994). Immuno-
suppression after transportation predisposes calves to 
developing bovine respiratory disease (BRD), which 
commonly occurs in the first 45 d of arrival and is as-
sociated with 65 to 80% morbidity and 35 to 55% mor-
tality (Cernicchiaro et al., 2012; Edwards, 1996; Speer 
et al., 2001). Bovine respiratory disease is estimated to 
cost the beef industry US$500 million annually (Miles, 
2009). Therefore, even a modest reduction in stress after 
transportation could have a significant economic benefit 
for livestock producers (Speer et al., 2001).
Transportation is associated with an increase in cir-
culating pro-inflammatory cytokines in cattle leading to 
the initiation of an inflammatory reaction (Arthington et 
al., 2003). Previous studies support the hypothesis that 
extended exposure to a nonsteroidal anti-inflammatory 
drug (NSAID) may reduce stress and improve perfor-
mance after castration and dehorning (Baldridge et al., 
2011; Coetzee et al., 2012b). Meloxicam (MEL) is an 
NSAID approved in Canada for pain relief in calves 
after disbudding and is used as an anti-inflammatory 
for dogs in the United States. Meloxicam was found to 
reduce the incidence of BRD in calves after castration 
when administered on arrival at the feedlot (Coetzee et 
al., 2011). However, a similar effect was not observed 
in calves received as steers. We hypothesized that MEL 
administration to beef steers before shipping may be ef-
fective at reducing the impact of transportation on stress 
biomarkers. The objective of this study was to assess 
stress biomarkers and inflammatory mediators in beef 
steers that received oral MEL or a placebo (CONT) be-
fore long-distance transportation.
MATERIALS AnD METHODS
Before the initiation of this experiment, all animal 
use, handling, and sampling techniques described were 
approved by the Iowa State University Animal Care and 
Use Committee (protocol number 5-12-7355-B).
Animals, Housing, Treatment Allocation, and Ship-
ment
This study was a randomized complete block design 
with cattle assigned to receive either oral MEL or a whey 
protein placebo before shipment based on bodyweight 
(Fig. 1). Ninety-seven medium-to-large frame, horned 
and polled, Brahman and Angus × Brahman crossbred 
steers aged 15 to 17 mo, weighing 201 to 465 kg, were 
procured from the Brown Loam Experiment Station 
at the Mississippi State University research farm near 
Raymond, MS, after a 32 wk backgrounding period. All 
calves received preweaning vaccinations for infectious 
bovine rhinotracheitis, bovine viral diarrhea types I and 
II, parainfluenza-3 virus, bovine respiratory syncytial vi-
rus (Pyramid 5; Boehringer Ingelheim, St. Joseph, MO), 
clostridial organisms (Ultra bac 7; Pfizer Animal Health, 
Madison, NJ), and Mannheimia haemolytica (One Shot; 
Pfizer Animal Health) and were dewormed at the facility 
with eprinomectin (Eprinex; Merial, Duluth, GA). Post-
weaning vaccinations consisted of a booster for all patho-
gens stated before the start of the backgrounding period.
Following weaning in October 2011, calves were held 
for 60 d in the Brown Loam Research Facility in Raymond, 
MS, feedlot. Calves were initially fed a diet of soy hull 
pellets at 2% of their BW followed by free choice hay and 
20% crude protein molasses. Animals were then main-
tained on ryegrass pastures until late June when they were 
allowed access to crabgrass and Bermuda grass pastures 
before shipping. If pasture was limited at any point in time, 
hay was provided. The hay in both instances contained 
mixed grasses but primarily consisted of Bermuda grass.
Baseline blood sample collection occurred at timepoint 
0, which was immediately followed by administration of 
MEL or the CONT. Calves were ranked by BW and as-
signed to either a MEL- or CONT-treated group by a ran-
domization table generated using Excel (Microsoft Corp., 
Redmond, WA). To facilitate dose determination and to 
minimize disruption during processing, calves were subdi-
vided into 3 groups based on weights determined at study 
enrollment. These groups were as follows: light (201–314 
kg), medium (319–370 kg), and heavy (380–465 kg) weight. 
At time zero (0 h) MEL tablets (MEL tablets United States 
pharmacopiea 15 mg [United States pharmacopiea 0378-
1089-01], lot number 3032625; Mylan Pharmaceuticals 
Inc., Morgantown, WV) were administered to the 3 groups 
so that the average weight per group resulted in a mean 
dose of 1 mg MEL/kg BW. The doses were calculated us-
ing pretreatment BW from the previous week in addition to 
adjusted weight gain during that week. When weighed, no 
restrictions to food or water were implemented. The light 
group (n = 31) received an actual dose of 0.9 to 1.4 mg/kg 
BW. The medium group (n = 33) received an actual dose 
of 0.89 to 1.0 mg/kg BW, and the heavy group (n = 33) 
received an actual dose of 0.90 to 1.1 mg/kg BW. Calves 
in the CONT-treated group received an equivalent dose of 
whey protein supplement product (Health-watchers, Inc., 
Bohemia, NY), a pharmaceutically inactive excipient used 
in the manufacture of MEL tablets. Both treatments were 
administered in gelatin capsule boluses (lot number 2634; 
Torpac, Fairfield, NJ). Whey protein was also added as filler 
to the capsules containing MEL tablets so that operators 
remained masked to treatment group.
After treatment, calves were shipped approximately 
1,316 km from Raymond, MS, to a feedlot facility near Ta-
bor, IA, in 2 truckloads carrying 48 and 49 calves, respec-
tively. Loading was coordinated for the trucks to arrive at 
the 24 h timepoint. Calves were blood sampled in Iowa on 
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10 July 2012 after a 16-h transportation event that concluded 
approximately 24 h after baseline blood collection. Calves 
were then maintained in an open pen of 192 m2 with an al-
lowance of approximately 0.69 m of bunk space per animal 
and 1 water source per pen. All calves were housed in the 
same pen. Upon arrival calves were fed a typical receiving 
diet composed of dry corn, dry distiller’s grain, corn silage, 
and a protein/vitamin/mineral supplement throughout the 
experiment. Feed and water were offered ad libitum. A final 
blood sample was collected at 5 d after arrival, 144 h after 
baseline sample collection at 0 h.
Collection of Samples
Blood samples were collected at 0, 24, and 144 h 
via direct puncture of the jugular vein to assess complete 
blood count (CBC) and to determine plasma concentra-
tions of MEL, total carbon dioxide (TCO2), haptoglobin 
(Hp)-matrix metalloproteinase-9 (MMP-9) complexes, 
tumor necrosis factor α (TnFα), cortisol, and substance 
P (SP). Blood samples were collected in 6 mL evacuated 
tubes that contained lithium heparin (Vacuette Heparin 
tubes; Greiner Bio-One, Monroe, NC; MEL and cortisol 
concentrations), serum separator tubes (Vacuette SST 
tubes; Greiner Bio-One; TCO2, TNFα, and Hp-MMP-9), 
or EDTA tubes (Vacuette K3 EDTA tubes; Greiner Bio-
One; CBC and SP concentrations). Benzamidine hydro-
chloride (lot number D1510; Santa Cruz Bio Technol-
ogy, Dallas, TX) was added to 1 of the EDTA tubes at 1 
mM per mL of whole blood to reduce endogenous prote-
ase-associated degradation of SP in the samples. Blood 
samples were centrifuged for 15 min at 1,600 × g ; 22° C. 
All samples were processed within 30 min of collection. 
Immediately after centrifugation, plasma was harvested, 
placed in cryovials, and frozen at –70°C until analysis.
Plasma Meloxicam Analysis
Plasma concentrations of MEL were determined us-
ing high-pressure liquid chromatography (Surveyor MS 
Pump and Autosampler; Thermo Scientific, San Jose, 
CA) with mass spectrometry detection (TSQ Quantum 
Discovery MAX; Thermo Scientific) as previously de-
scribed (Kreuder et al., 2012). The accuracy of the assay 
Figure 1. Flow chart outlining the timeline of study events that occurred at timepoints 0, 24, and 144 h. Treatment with either meloxicam at 1 mg/kg or 
a placebo was administered at time 0 h after baseline blood sample collection. Follow-up blood sample collection for determination of biomarkers and drug 
concentrations occurred after a 16 h (1,316 km) transportation event and 120 h thereafter.
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for MEL in bovine plasma was 99 ± 3% of the actual 
concentration while the coefficient of variation was 5% 
determined on 4 sets of replicates for each of the follow-
ing concentrations: 15, 150, and 1,500 ng/mL.
Cortisol Analysis
Plasma cortisol concentrations were determined 
by RIA using a cortisol kit (Siemens Coat-a-Count 
Kit; Siemens, Malvern, PA) according to the manufac-
turer instructions. The range of detection was from 3 
to 1,000 ng/mL. The coefficient of variation for intra-
assay variability was 10% and the interassay variability 
was calculated at <15%.
Substance P Analysis
Substance P concentrations were analyzed as de-
scribed by Liu et al. (2008) using nonextracted plasma. 
Method validation using nonextracted plasma con-
sisted of complete recovery (±15%) of a known SP 
concentration added to pooled baseline plasma. Plas-
ma concentrations of SP were analyzed by RIA using 
double antibody system with a primary antibody vs. SP 
(1:60,000, lot number H-061-0, purchased from Phoe-
nix Pharmaceuticals, Burlingame, CA) and 125I-sub-
stance P (20,000 counts per minute) purchased from 
PerkinElmer Inc. (Waltham, MA). Ethylenediaminetet-
raacetic acid (13 mM) immunoassays have been used 
previously to determine SP concentrations and have 
been validated for use with bovine plasma (Coetzee et 
al., 2008; Theurer et al., 2013). The assay had a deter-
mination range of 5 to 160 pg/mL. The coefficient of 
variation for intra-assay variability was at 11% and the 
interassay variability was calculated at 4%.
Total Serum Carbon Dioxide Analysis
Total carbon dioxide concentration was analyzed 
using the serum collected from steers at 0 and 24 h. 
Samples were centrifuged immediately after collection 
and all analyses were completed within 48 h after col-
lection to minimize the effect of sample handling on 
TCO2 concentrations (Tinkler et al., 2012). The sam-
ples were analyzed using Nova 4, a total CO2 analyzer 
(Nova Biomedical, Waltham, MA) following the man-
ufacturer’s instructions. Data analysis was completed 
through the use of a known carbon dioxide standard kit 
(Verichem Laboratories, Providence, RI).
Tumor Necrosis Factor α Analysis
Tumor necrosis factor α was analyzed using a bo-
vine TNFα ELISA test that was previously validated by 
Farney et al. (2011). The optical density was then mea-
sured at 450 and 550 nm using a plate reader (Power-
WaveXS; BioTek Instruments Inc., Winooski, VT). The 
corrected difference values were fit to the standard curve 
by point-to-point regression. Values of detection ranged 
from 3.9 to 250 pg/mL with intra-assay and interassay 
critical variances of 14.1 and 15.9%, respectively.
Haptoglobin-Matrix Metalloproteinase-9 Analysis
An ELISA specific for bovine neutrophil Hp in com-
plex with MMP-9 was performed as described previously 
(Bannikov et al., 2011) with minor alterations. Standard 
concentrations ranged from 1.78 to 456 ng/mL, which 
represent the upper and lower limits of quantitation of 
the assay, respectively. The concentration of Hp-MMP-9 
was determined using the linear portion of the equation 
of the line described by absorbance of the calibrators at 
450 nm and the known concentration of these calibra-
tors. Any sample remaining outside of the range of the 
standard curve (>456 ng/mL) were further diluted and 
reanalyzed. Between-plate variability of calibrators from 
5 plates was less than 3% (median = 1.8%; range 0.98–
2.7%). The average correlation coefficient determined by 
linear regression of the absorbance versus concentration 
of the calibrators was 0.91 (range 0.85 to 0.95). The ana-
lytical sensitivity of the assay was 3.5 ng/mL.
Clinical Pathology Analysis
The Iowa State University Clinical Pathology Labo-
ratory determined the CBC using the ADVIA 120 analyz-
er (Siemens) using a program specific for bovine blood. 
This automated process measures total white blood cell 
count, white blood cell differential, red blood cell count, 
platelet counts, hemoglobin, fibrinogen, mean corpuscle 
volume (MCV), mean corpuscle hemoglobin concentra-
tion (MCHC), mean corpuscle hemoglobin (MCH), red 
blood cell distribution width (RDW), and hematocrit.
Statistical Analysis
The statistical analysis of the study was performed 
using SAS (version 9.2; SAS Inst. Inc., Cary, NC). Re-
sponses were analyzed using linear mixed models with 
repeated measures. Animal was the subject of repeated 
measures whereas truck was included in the model as a 
random effect. Two structures of fixed effects were con-
sidered. One is ANOVA structure with treatment group, 
time, and their interaction; the other is an analysis of co-
variance type with MEL concentration (continuous) and 
time (categorical) included in the model. Furthermore, 
matrix metalloproteinase (Hp-MMP-9) values were 
analyzed following quantification of Hp-MMP-9 as ei-
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ther having the presence (“yes”) or absence (“no”) of the 
protein in measurable quantities. A mixed effect logistic 
regression model that contained repeated measures was 
used to describe the data.
Model assumptions were considered to be appro-
priately met based on diagnostics conducted on stu-
dentized residuals. Estimated least square means and 
corresponding standard errors, or 95% confidence in-
tervals, are presented. A significant difference was con-
sidered to be present when P ≤ 0.05, and a marginal 
difference was considered to exist if 0.05 < P ≤ 0.10. 
Relevant pairwise comparisons were conducted when 
the significance of the interaction term was P ≤ 0.10 
using Tukey-Kramer or Bonferroni adjustments, as ap-
propriate in each case, to avoid inflation of Type I error 
rate due to multiple comparisons.
RESULTS AND DISCUSION
Meloxicam is an NSAID of the oxicam class that 
is approved in the European Union and Canada for ad-
junctive therapy of acute respiratory disease, diarrhea, 
and acute mastitis and the alleviation of pain associ-
ated with disbudding in calves when administered at 
0.5 mg/kg intravenously or subcutaneously (EMEA, 
2009). Meloxicam administered to cattle by any route 
constitutes extra-label drug use (ELDU) because 
there are currently no analgesic drugs specifically ap-
proved to provide pain or stress relief in livestock in 
the United States (Smith and Modric, 2013). Under the 
Animal Medicinal Drug Use Clarification Act of 1994 
(AMDUCA), ELDU is permitted only under veterinary 
supervision “when the health of an animal is threat-
ened, or suffering or death may result from failure to 
treat” provided specific conditions are met (U.S. Food 
and Drug Administration, 1994, 530.2). In the absence 
of U.S. Food and Drug Administration–approved an-
algesic compounds in food animals, use of oral MEL 
tablets for alleviation of pain or stress in cattle can be 
considered under AMDUCA. To our knowledge, this 
is the first published report evaluating the effect of a 
long-acting NSAID on the stress response in cattle 
after long-distance transportation. Further studies are 
needed to assess if this translates to improved health 
and performance on arrival at the feedlot.
Plasma Meloxicam Concentrations
None of the calves had detectable plasma MEL con-
centrations in samples collected at the baseline time-
point. Mean (±SEM) plasma MEL concentrations in 
MEL-treated calves ranged from 1,868 ± 92.16 ng/mL 
on arrival at the feedlot (24 h after dosing) to 38.38 ± 
6.18 ng/mL at 144 h after dosing. There was no differ-
ence in plasma MEL concentrations between the 3 dif-
ferent weight categories of calves that were used for 
dose determination (P = 0.90). There were also no MEL 
detected in calves assigned to the CONT group.
The pharmacokinetics of MEL after oral admin-
istration at 1 mg/kg indicate that a peak plasma con-
centration of approximately 3 μg/mL occurs at around 
12 h after administration with an elimination half-life 
(T 1/2) of about 28 h (Coetzee et al., 2009, 2011). In 
the present study, the mean MEL concentration deter-
mined at 24 h after oral administration was less than 
the peak concentration previously reported. However, 
the mean concentration of MEL recorded at 144 h rep-
resents a T 1/2 of approximately 24 h and is consistent 
with the level expected after approximately 5 to 6 plas-
ma elimination half-lives. Taken together the results of 
this study suggest that MEL administered at 1 mg/kg 
provided circulating MEL concentrations for up to 5 d 
after oral administration.
Body Weight
Calves experienced a characteristic decrease in BW 
after the transportation event known as “shrink.” This 
weight loss was reported as a time effect (P < 0.001) with 
no treatment effect observed between groups (P = 0.67; 
Fig. 2). Furthermore, there was no association between 
plasma MEL concentrations and shrink (P = 0.78; Table 1). 
These results are consistent with previously reported stud-
ies evaluating weight loss following transportation from 
a North American review on animal welfare (Schwartz-
kopf-Genswein et al., 2012). The observed weight loss 
in this study is consistent with previous reports in the lit-
erature. However, the calves in our study showed an 8% 
loss in BW where as Arthington et al. (2003) reported a 
2 to 3% loss in BW after a 3-h transportation event and 
Buckham Sporer et al. (2008) reported shrinkage of 10% 
in calves (approximately 230 kg) transported for over 9 
h. This supports the hypothesis that percentage of weight 
loss during transportation is likely associated with the du-
ration of the transportation event as was previously sug-
gested (Cernicchiaro et al., 2012).
Cortisol
Serum cortisol concentrations were affected by time 
(P < 0.0001) in both the MEL and CONT groups. The 
concentration of cortisol decreased from baseline to 24 h 
after transportation and increased marginally at the 144-
h sample collection (Fig. 3). The present study provided 
evidence of a time × treatment interaction on cortisol 
response (P = 0.04) and an inverse relationship between 
circulating cortisol concentrations and MEL concentra-
tions (P = 0.0017; Table 1).
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The decrease in cortisol observation contradicts pre-
vious published reports that demonstrate an increase in 
cortisol ranging from 5.8% in 2 to 3 wk mixed breed 
calves transported for 8 to 24 h in duration (Knowles et 
al., 1997) to 311% in 4 to 6 mo old dairy calves trans-
ported for 4 h (Murata et al., 1987). Elevated cortisol 
concentrations in serum are maintained after exogenous 
ACTH stimulation for approximately 2 h (Lay et al., 
1996). The longer travel time in the present study may 
have allowed calves to become acclimated to their sur-
roundings, thus reducing blood cortisol levels while on 
the truck in transit. Moreover, the sample obtained at 24 
h may not have coincided with peak cortisol concentra-
tions following transportation.
The observed time × treatment effect was likely due 
to the combined anti-inflammatory and analgesic effect 
of NSAID in addition to a proposed direct modulation 
of ACTH release resulting in a reduction in circulating 
cortisol concentrations (Watson et al., 2009). Recently, 
Geary (2012) reported that circulating cortisol concen-
tration in cows receiving the NSAID flunixin meglu-
mine was numerically less than control cows after injec-
tion of ACTH to mimic transportation stress. It is likely 
that this study, which comprised only 20 animals, lacked 
sufficient statistical power to detect a significant differ-
ence between groups. Taken together, the relationship 
between NSAID administration and stress reduction af-
ter transportation warrants further investigation to deter-
mine if this results in improved health and performance 
of calves after long-distance transportation.
Haptoglobin-Matrix Metalloproteinase-9 Complexes
The majority of the serum samples contained <15 
ng/mL Hp-MMP-9 complexes (253/288 samples). 
Therefore, in addition to conducting a repeated measures 
analysis on the positive results, we also chose to classify 
samples as positive or negative based on the cutoff of 
<15 ng/mL (negative) and >15 ng/mL (positive). Overall 
2.1% of the calves were positive at first sampling time, 
15.6% were positive at 24 h after arrival, and 18.9% 
were positive at 4 d after arrival. However, using this 
analysis there was no effect of treatment (P = 0.97), time 
(P = 0.88), or time × treatment interaction (P = 0.59).
In the calves that did demonstrate quantifiable in-
creases in Hp-MMP-9 complexes, a time effect (P = 
0.0061) was observed in both treatment groups (Fig. 4) 
but no treatment effect (P = 0.88) was observed. There 
was also no evidence of a relationship between MEL 
concentrations and log Hp-MMP-9 (P = 0.74; Table 1).
Matrix metalloproteinases regulate the degradation 
of extracellular matrix protein components and modu-
lates cytokine activation through in vivo cleavage. Ban-
nikov et al. (2007) reported that neutrophil MMP-9 is 
covalently complexed with neutrophil synthesized Hp 
suggesting that this is a potentially useful biomarker 
indicating activation and degranulation of neutrophils 
(Theurer et al., 2013). Increases in plasma Hp-MMP-9 
concentration over time are consistent with other stud-
ies reporting significantly elevated plasma Hp-MMP-9 
concentrations in cattle with acute inflammation (Ban-
nikov et al., 2011). A number of disorders commonly 
diagnosed in cattle are characterized by a significant 
mobilization and activation of neutrophils (Slocombe et 
al., 1985). The present study documents for the first time 
that plasma concentrations of Hp-MMP-9 are associated 
with physiologic alterations during transportation.
Fibrinogen
Circulating fibrinogen concentration was not sig-
nificantly affected by transportation (P = 0.17) or MEL 
Figure 2. Mean ± SE for BW change (kg) after treatment with 1 mg/kg 
meloxicam or a placebo at 0 h followed by a 16 h (1,316 km) transportation 
event. Letters that are the same indicate data points that are not significantly 
different (P < 0.05).
Table 1. Intercept and slope of chemistry biomark-
ers and bodyweight change with SE for the correlation 















Bodyweight, kg 354.34 0.08 0.30 0.78
Log cortisol, ng/mL 37.19 –1.51 0.47 0.0017
Substance P, pg/mL 26.06 0.16 0.78 0.89
Plasma protein, g/dL 6.96 –0.01 0.01 0.32




1.42 –0.02 0.05 0.74
Total carbon dioxide, 
mM
24.91 –0.01 0.06 0.90
Tumor necrosis 
factor-alpha, pg/mL
168.05 0.09 1.91 0.96
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administration (P = 0.41; Table 2). There was also no 
association between MEL concentrations and fibrinogen 
(P = 0.42; Table 1). Fibrinogen maintains homeostasis 
by providing a substrate for fibrin formation and tis-
sue repair (Murata et al., 2004). Fibrinogen results for 
cattle during transportation remain equivocal. A 133% 
increase in fibrinogen was reported in a study with 32 
calves that were transported for 3 h (Arthington et al., 
2003). Conversely, a 28% reduction in fibrinogen over 
48 h after transportation was reported in a study involv-
ing 36 calves transported for 9 h (Buckham-Sporer et 
al., 2008). Therefore the usefulness of fibrinogen as a 
biomarker of inflammation after transportation requires 
further investigation.
Plasma Protein
Plasma protein concentrations increased over time 
after transportation (P < 0.0001), most notably at the 
24-h sampling timepoint (P < 0.001) as illustrated in 
Table 1. Plasma protein was unaffected by treatment (P = 
0.32) and there was no association between plasma MEL 
concentrations and plasma protein (P = 0.32; Table 1). 
Hyperproteinemia was anticipated after transportation 
as a result of dehydration due to inadequate water in-
take and water loss during shipping. This observation is 
in agreement with previous reports (Parker et al., 2003; 
Earley et al., 2006a; Earley and O’Riordan, 2006b). 
However, another study reported a decrease in plasma 
protein after a 9-h transportation event (Buckham Sporer 
et al., 2008). This was attributed to altered protein me-
tabolism associated with transportation or differences 
in the nutritional status of animals immediately before 
transportation. It was also reported that breed may in-
fluence plasma protein concentrations but these effects 
could not be established in the present study.
Tumor Necrosis Factor α
A significant increase in circulating TNFα concen-
trations was observed after transportation (P < 0.001; 
Fig. 5). However, there was no effect of MEL admin-
istration on TNFα concentration (P = 0.79). There was 
also no association between plasma MEL concentrations 
and TNFα concentrations (P = 0.96; Table 1).
Figure 3. Mean ± SE for serum cortisol concentrations after treatment 
with 1 mg/kg meloxicam or a placebo at 0 h followed by a 16 h (1,316 km) 
transportation event. Letters that are the same indicate data points that are not 
significantly different (P < 0.05).
Figure 4. Mean ± SE for plasma log haptoglobin (Hp)-matrix metallo-
proteinase-9 (MMP-9) complexes concentrations after treatment with 1 mg/
kg meloxicam or a placebo at 0 h followed by a 16 h (1,316 km) transporta-
tion event. Letters that are the same indicate data points that are not signifi-
cantly different (P < 0.05).
Table 2. Comparison between the least squares (LS) means ± SE serum chemistry biomarkers at 0, 24, and 144 h 
















Time × trtLS means ± SE LS means ± SE LS means ± SE
Plasma protein, g/dL 6.9–7.7 CONT 7.02a ± 0.07 7.40b ± 0.07 7.00a ± 0.07 0.32 <0.0001 0.18
MEL 7.02a ± 0.07 7.32b ± 0.07 6.88b ± 0.07
Total carbon dioxide, 
mM
CONT 22.77a ± 0.33 24.98b ± 0.34 0.51 <0.0001 0.77
MEL 22.43a ± 0.33 24.81b ± 0.33
Fibrinogen, mg/dL 100–500 CONT 438.11 ± 24.68 462.39 ± 24.68 483.8 ± 25.09 0.41 0.173 0.30
MEL 426.23 ± 24.30 477.62 ± 24.12 433.85 ± 25.54
a,bDifferent superscripts indicate significant differences between timepoints in a row after transportation (P < 0.05).
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Cytokines are signaling proteins produced primar-
ily by macrophages in response to infection, tissue inju-
ry, or stress. Elevated levels of TNFα increase vascular 
permeability of endothelial cells, which allows for the 
increased entry of immunoglobulin, complement, and 
other cells to damaged tissue (Janeway et al., 2012). An 
increase in cytokine production after transportation was 
anticipated based on a recent publication that reported 
a 40% increase in TNFα at 48 h after a 4-h transit event 
(Hulbert et al., 2011). Although a recent study indicated 
a reduction of TNFα in calves with BRD treated with 
MEL and oxytetracycline, a treatment effect was not 
observed in the present study (Bednarek et al., 2003). 
The direct mechanism behind this effect is poorly un-
derstood and requires further investigation.
Substance P
An increase in plasma SP concentrations was ob-
served after transportation (P < 0.0026; Fig. 6), but 
there was no treatment effect (P = 0.13) or time × treat-
ment interaction (P = 0.45). There was also no associa-
tion between plasma MEL concentrations and SP (P = 
0.89; Table 1).
Substance P is an 11–amino acid neuropeptide as-
sociated with areas of the neuroaxis involved in the 
integration of pain, stress, and anxiety (Devane, 2001; 
Coetzee et al., 2008). The present study supports the re-
sults of a recently reported 46% SP increase following 
4 h of transportation (Theurer et al., 2013). Although 
an inverse linear relationship of MEL and SP has been 
recently reported in a dehorning study (Coetzee et al., 
2012), MEL administration did not reduce SP in the 
present study. The absence of an effect could be as-
sociated with a reduced magnitude of SP release after 
transportation compared with dehorning.
A wide variety of physical and psychological stress-
ors can stimulate release of SP. Pulmonary exposure to 
diesel exhaust fumes, ozone, allergens, carbon dioxide, 
and cigarette smoke can elicit SP release in airways in 
rats (Wong et al., 2004a,b). The role of SP in the patho-
genesis of BRD has yet to be elucidated. In experimen-
tal M. haemolytica infection in sheep there was strong 
immunoreactivity for SP on macrophages infiltrating 
into the inflamed areas on d 1 postinfection (Ramirez-
Romero et al., 2001; Grubor et al., 2004). Furthermore, 
exposure of alveolar macrophages to SP resulted in 
enhanced phagocytosis and increased tumor necrosis 
factor production compared to nonstimulated controls 
(Rogers et al., 2006). An increase in vascular perme-
ability in response to SP exposure has also been dem-
onstrated (Ragsdale et al., 2008). Taken together these 
studies indicate that transportation increases SP release 
and that this may be associated with the development 
of pulmonary inflammation that may contribute to the 
pathogenesis of BRD. However, administration of an 
NSAID appeared to be ineffective at directly mitigat-
ing SP release after shipping in the present study.
Total Carbon Dioxide
There was an increase in TCO2 during transit (P < 
0.0001; Table 2) but there was no treatment effect (P = 
0.51) or association between plasma MEL concentra-
tions and TCO2 (P = 0.90; Table 1).
An increase in TCO2 after shipping has been previ-
ously reported as a result of a decrease in potassium, 
chloride, and water from sweating (Stockham et al., 
2008). However, in a study investigating the partial 
pressure of carbon dioxide after transportation, no dif-
ference was reported for transported steers compared 
to control animals (Parker et al., 2003). Total carbon 
Figure 6. Mean ± SE for plasma substance P concentrations after treat-
ment with 1 mg/kg meloxicam or a placebo at 0 h followed by a 16 h (1,316 
km) transportation event. Letters that are the same indicate data points that are 
not significantly different (P < 0.05).
Figure 5. Mean ± SE for serum tumor necrosis factor-α (TNFα) concen-
trations after treatment with 1 mg/kg meloxicam or a placebo at 0 h followed 
by a 16 h (1,316 km) transportation event. Letters that are the same indicate 
data points that are not significantly different (P < 0.05).
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dioxide of serum or plasma provides a measure of acid–
base balance due to metabolic changes. The increase in 
TCO2 observed in the present study is likely indicative 
of either a metabolic or respiratory alkalosis (Dehkordi 
and Dehkordi, 2011). Metabolic alkalosis is most fre-
quently associated with digestive disturbances in rumi-
nants. Respiratory alkalosis is caused by hyperventila-
tion, which may be stimulated by pulmonary disease 
or heat stress. Both types of alkalosis may therefore 
be present during long-distance transportation where 
animals are subjected to food deprivation and exposed 
to changes in environmental temperature.
Hematology
Time effects were observed for all hematological 
data (P < 0.05), except for basophil count (P = 0.84) 
and MCHC (P = 0.45; Table 3). Treatment effects were 
observed for total leukocyte counts (P = 0.01), MCV 
(P = 0.05), MCH (P = 0.05), and lymphocyte count (P = 
0.05; Table 4). A time × treatment interaction was evi-
dent for monocyte count (P = 0.04) and a trend towards 
an interaction was observed for RDW (P = 0.07) and 
neutrophil count (P = 0.10).
A stress leukogram, characterized by a mature 
neutrophilia, lymphopenia, and monocytosis, was ob-
served in both groups following transportation. The 
administration of MEL appeared to attenuate the de-
velopment of a stress leukogram as evidenced in the 
response variables discussed below.
A neutrophilia (P < 0.0001) observed across both 
groups after transportation (Fig. 7) is consistent with re-
sults from previous studies (Blecha et al., 1984; Buck-
ham Sporer et al., 2008; Burdick et al., 2011). The in-
crease in the mean number of circulating neutrophils 
recorded in the CONT group on arrival at the feedlot 
was greater than in the MEL group (P = 0.0072; Table 4). 
Neutrophil count was also inversely proportional to 
plasma MEL concentrations providing further evidence 
of a treatment response (P = 0.04; Table 5).
A stress neutrophilia is the result of the corticoste-
roid-induced release of mature cells from the bone mar-
row and the reduced margination and migration of neu-
trophils out of the vasculature (Benschop et al., 1996; 
Jones et al., 2007). Several studies have determined the 
functional capacity of the immune response using in vitro 
tests after transport. Murata et al. (1987) observed that 
nitroblue tetrazolium reduction activity of neutrophils 
was initially reduced by 10% on arrival followed by a 
36% increase at 4 h after transport. Similarly, Burdick 
et al. (2011) found that cattle had decreased phagocytic 
neutrophil intensity at 48 h posttransit and that calm bulls 
had more active neutrophils with greater phagocytosis 
and oxidative burst intensities to Escherichia coli than 
temperamental bulls at 96 h. These findings indicate that, 
although the relative number of neutrophils is increased 
after transportation, the functional capacity of these cells 
is decreased leading to immune compromise. The mitiga-
tion of the stress neutrophilia in the present study and the 
negative association between MEL concentrations and 
neutrophil count suggests that MEL may have reduced 
Table 3. Comparison between the least squares (LS) means ± SE of red blood cell parameter data at 0, 24, and 144 h 
after treatment (trt) with 1 mg/kg meloxicam (MEL) or a placebo (CONT) before transportation at 0 h, after transpor-
tation at 24 h, and at 144 h thereafter
Parameter Normal 
range
Trt group Time, h P-values
0 24 144 Trt Time Time × trt
LS means ± SE LS means ± SE LS means ± SE
Red blood cell, 103 cells/μL 5.0–10.0 CONT 8.47a ± 0.14 8.59a ± 0.14 8.19b ± 0.14 0.13 <0.0001 0.38
MEL 8.80a ± 0.14 8.79a ± 0.14 8.50b ± 0.14
Hemoglobin, g/dL 8.0–15.0 CONT 11.75a ± 0.15 12.00b ± 0.15 11.27c ± 0.15 0.98 <0.0001 0.17
MEL 11.83a ± 0.15 11.85a ± 0.15 11.33b ± 0.15
Hematocrit, % 24.0–46.0 CONT 33.12a ± 0.43 33.94b ± 0.43 31.90c ± 0.44 1.00 <0.0001 0.20
MEL 33.42a ± 0.42 33.52a ± 0.42 32.04b ± 0.43
Mean corpuscle volume, fL 40.0–60.0 CONT 39.27a ± 0.45 39.69b ± 0.45 39.15a ± 0.45 0.05 <0.0001 0.20
MEL 38.17a ± 0.44 38.33a ± 0.44 37.91b ± 0.44
Mean corpuscle hemoglobin, Pg 11.0–17.0 CONT 13.95a ± 0.18 14.03a ± 0.18 13.83b ± 0.18 0.05 <0.0001 0.61
MEL 13.51ab ± 0.18 13.55a ± 0.18 13.41b ± 0.18
Mean corpuscle hemoglobin 
concentration, g/dL
30.0–36.0 CONT 35.52 ± 0.16 35.35 ± 0.16 35.35 ± 0.17 0.87 0.46 0.70
MEL 35.40 ± 0.16 35.37 ± 0.16 35.37 ± 0.17
Red blood cell distribution 
width, %
8.0–15.0 CONT 18.78a ± 0.27 18.42b,x ± 0.27 18.97a ± 0.27 0.14 <0.0001 0.07
MEL 19.00 ± 0.27 18.95y ± 0.27 19.20 ± 0.27
a,b,cDifferent superscripts indicate significant differences between timepoints in a row after transportation (P < 0.05).
x,yDifferent superscripts indicate significant differences between treatment groups in the related CONT and MEL columns after transportation (P < 0.05).
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some of the negative impacts of transportation stress on 
immune function. Further studies evaluating immune cell 
function are planned to characterize this effect further.
Lymphocyte counts decreased from before shipping 
to arrival in both the CONT (P < 0.0001) and MEL (P < 
0.0005) groups (Table 4). A further reduction in lym-
phocyte count was observed between arrival and 120 h 
later in both the MEL (P = 0.01) and CONT (P = 0.0001) 
groups. The reason for the observed treatment effect of 
MEL was likely due the greater lymphocyte count in the 
CONT calves before shipping because no time × treat-
ment interaction was evident (Fig. 8).
Exposure to corticosteroids causes redistribution of 
circulating lymphocytes into lymphoid compartments 
resulting in the development of a lymphopenia (Burton 
and Kehrli., 1996). Murata et al. (1987) reported a 90% 
decrease in T-lymphocyte numbers of 4- to 6-mo-old 
calves transported 4 h but no change in the number of 
B lymphocytes. Buckham Sporer et al. (2008) reported 
a 20% increase in leucocyte count from 4.5 to 14 h af-
ter initiation of a 9-h transportation event followed by a 
decrease ranging from 7 to 24% at 24 and 48 h, respec-
tively. Hulbert et al. (2011) reported an 86% increase in 
the neutrophil:mononuclear cell ratio at 24 h posttransit. 
This observation is similar to the results of the present 
Table 5. Intercept and slope of hematological biomark-
ers with SE for the correlation between meloxicam 














Basophils, 103 cells/μL 0.08 0.00 0.00 0.03
Neutrophil, 103 cells/μL 2.58 –0.07 0.03 0.04
Hemoglobin, g/dL 11.34 –0.03 0.02 0.06
Hematocrit, % 32.08 –0.09 0.05 0.07
Red blood cell distribution 
width, %
19.05 0.03 0.02 0.07
White blood cell, 103 cells/μL 9.05 –0.07 0.05 0.12
Red blood cell, 106 cells/μL 8.37 –0.02 0.01 0.20
Monocyte, 103 cells/μL 0.47 –0.01 0.00 0.27
Mean corpuscle volume, fL 38.52 –0.02 0.02 0.27
log mean platelet volume, fL 2.07 0.01 0.01 0.30
Neutrophil:lymphocyte ratio, 
103 cells/μL
2.54 –0.05 0.06 0.42
Platelet, 103 cells/μL 508.83 2.78 3.60 0.44
Mean corpuscle hematocrit, 
g/dL
35.35 0.01 0.02 0.73
Mean corpuscle hemoglobin, 
pg
13.61 0.00 0.01 0.79
Lymphocyte, 103 cells/μL 5.45 –0.01 0.03 0.80
Table 4. Comparison between the least squares (LS) means ± SE of white blood cell parameter data at 0, 24, and 
144 h after treatment (trt) with 1 mg/kg meloxicam (MEL) or a placebo (CONT) before transportation at 0 h, after 











0 24 144 Trt Time Time × trt
LS means ± SE LS means ± SE LS means ± SE
Platelet, 103 cells/μL 100–800 CONT 389.47a ± 23.25 392.62a ± 23.25 534.26b ± 23.57 0.81 <0.0001 0.14
MEL 395.53a ± 22.80 409.78a ± 22.80 490.79b ± 23.75
Neutrophil, 103 cells/μL 0.6–4.0 CONT 1.89a ± 0.23 3.88b,x ± 0.23 2.54c ± 0.24 0.10 <0.0001 0.10
MEL 1.75a ± 0.23 3.18b,y ± 0.23 2.42c ± 0.24
Lymphocyte, 103 cells/μL 2.5–7.5 CONT 7.32a,x ± 0.41 6.31b ± 0.41 5.69c ± 0.41 0.05 <0.0001 0.29
MEL 6.43a,y ± 0.41 5.73b ± 0.41 5.20c ± 0.41
Neutrophil:lymphocyte ratio, 
103 cells/μL
CONT 4.90a ± 0.70 3.16b ± 0.70 2.41b ± 0.71 0.31 <0.0001 0.47
MEL 4.51a ± 0.70 2.26b ± 0.69 2.51b ± 0.71
Monocyte, 103 cells/μL 0.03–0.85 CONT 0.39a ± 0.03 0.55b,x ± 0.03 0.45a ± 0.03 0.27 0.0001 0.04
MEL 0.38a ± 0.03 0.44ab,y ± 0.03 0.47b ± 0.03
Basophils, 103 cells/μL 0–0.2 CONT 0.08 ± 0.01 0.08 ± 0.01 0.07 ± 0.01 0.08 0.8336 0.11
MEL 0.07 ± 0.01 0.07 ± 0.01 0.07 ± 0.01
a,b,cDifferent superscripts indicate significant differences between timepoints in a row after transportation (P < 0.05).
x,yDifferent superscripts indicate significant differences between treatment groups in the related CONT and MEL columns after transportation (P < 0.05).
Figure 7. Mean ± SE for circulating neutrophil counts after treatment 
with 1 mg/kg meloxicam or a placebo at 0 h followed by a 16 h (1,316 km) 
transportation event. Letters that are the same indicate data points that are not 
significantly different (P < 0.05).
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study and is consistent with the development of a stress 
leukogram after transport.
Monocyte counts increased from before shipping to 
arrival in the CONT (P < 0.0001) but not the MEL (P = 
0.18) group (Table 4; Fig. 9). Exposure to corticoste-
roids also causes mobilization of marginated monocytes 
within the vasculature resulting in the development of a 
monocytosis (Latimer et al., 2003). Burdick et al. (2011) 
reported an 8% increase in peripheral mononuclear cells 
after a 4-h transportation event (P = 0.056). This ob-
servation is similar to the results of the present study 
and is consistent with the development of a stress leuko-
gram after transport. The concurrent mitigation of both 
the monocytosis and neutrophilia in the present study 
provides further support for the hypothesis that MEL 
reduced some of the negative impacts of transportation 
stress on immune function.
Basophilia in mammalian blood smears is seldom 
dramatic but an increase in circulating basophil count 
has been associated with stress in birds (Latimer and 
Prasse, 2003). In the present study there was no effect 
of time or treatment on basophil count (Table 4). How-
ever, there was a negative association between circulat-
ing MEL concentration and basophil count (P = 0.03; 
Table 5). To our knowledge there have been no studies 
that have specifically investigated the effect of transpor-
tation on basophil count. Given the absence of an overall 
effect of treatment and transportation despite a negative 
association with MEL, basophils appear to have limited 
utility in assessing stress in cattle.
A treatment effect was evident for both MCH (P = 0.05) 
and MCV (P = 0.05) with an observed decrease in MEL 
calves compared to CONT calves (Table 3). Although val-
ues remained in the laboratory’s reference range for normal 
limits, this effect may be the result of decreased synthesis 
of PGE2 associated with cyclooxygenase inhibition after 
NSAID administration. Prostaglandin E2 has demonstrated 
both enhancement and maintenance of haemopoietic stem 
cell activity and increases in MCH and MCV are usually 
associated with hematopoiesis (North et al., 2007; Hoggatt 
et al., 2009). Therefore, compounds that decrease PGE2 
synthesis could potentially decrease stem cell activity re-
sulting in a decreased MCH and MCV.
A time × treatment interaction was evident in RDW (P = 
0.07) with the distribution width being less in CONT calves 
compared with MEL calves (P = 0.03) on arrival (Table 3). 
There was no effect of time on RDW in the MEL-treated 
group. However, a weak positive association between MEL 
concentrations and RDW (P = 0.07) was observed.
Red blood cell distribution width is a measure of 
variation in the size of the red blood cells. It is a calcu-
lated parameter representing the coefficient of the varia-
tion of the MCV (Subhashree et al., 2013). It is therefore 
not surprising that a difference in RDW was observed in 
the present study because MCV was less in MEL-treated 
calves (P = 0.05). In a previous study, Fazio et al. (2011) 
observed an increase in RDW in sheep transported 125 
km by road for 3 h but no explanation was offered for 
why this observation occurred. It has been suggested 
that an increase in RDW can be used as a biomarker to 
identify pulmonary compromise but the conflicting re-
sults presented in these reports suggest that additional 
studies are needed to investigate this relationship further.
The overall results of this study suggest that long-dis-
tance transportation was associated with a significant in-
crease in neutrophil, platelet, monocyte, white blood cell, 
and red blood cell count after shipping and a decrease 
in lymphocyte count. Furthermore, MMP-9 complexes, 
TCO2, TNFα, plasma proteins, and SP increased and cor-
tisol concentrations decreased after shipping. Meloxicam 
treatment reduced the stress neutrophilia and monocy-
tosis after shipping. Circulation cortisol, neutrophil, and 
basophil concentrations were also inversely proportional 
to plasma MEL concentrations. Further studies, including 
examination of the effect of MEL administration on cell 
function, calf health, and performance, are needed to fully 
elucidate the overall impact of NSAID administration on 
Figure 8. Mean ± SE for circulating lymphocyte counts after treatment 
with 1 mg/kg meloxicam or a placebo at 0 h followed by a 16 h (1,316 km) 
transportation event. Letters that are the same indicate data points that are not 
significantly different (P < 0.05).
Figure 9. Mean ± SE for circulating monocytes counts after treatment 
with 1 mg/kg meloxicam or a placebo at 0 h followed by a 16 h (1,316 km) 
transportation event. Letters that are the same indicate data points that are not 
significantly different (P < 0.05).
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the negative effects of long-distance transportation. These 
findings may have implications for developing strategies 
to reduce the impact of transportation stress on the health 
and performance of feedlot cattle.
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